Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting

Reuters04-10 18:59

Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting

Viatris outlined four data presentations for ASCRS Annual Meeting in Washington, D.C., April 10-13, including new Phase 3 readouts for phentolamine ophthalmic solution programs.
Full results from VEGA-3, Phase 3 study of MR-141 for presbyopia, will be presented, highlighting durable improvement in near vision.
LYNX-2 Phase 3 data on MR-142 in post-refractive surgery patients will be presented as an encore, supporting use in low-light visual disturbance.
Post-hoc analysis from MIRA-2 Phase 3 study will be shown, indicating RYZUMVI can improve image quality when reversing pharmacologically induced pupil dilation.
Phase 1 study results for varenicline solution nasal spray in healthy Japanese adults will be presented, focusing on tear-related effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604100659PR_NEWS_USPR_____NE31355) on April 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626191297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626191297","market":"fut","top_or_hot":-1,"title":"Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Viatris outlined four data presentations for ASCRS Annual Meeting in Washington, D.C., April 10-13, including new Phase 3 readouts for phentolamine ophthalmic solution programs.\n        </li>\n<li>\n          Full results from VEGA-3, Phase 3 study of MR-141 for presbyopia, will be presented, highlighting durable improvement in near vision.\n        </li>\n<li>\n          LYNX-2 Phase 3 data on MR-142 in post-refractive surgery patients will be presented as an encore, supporting use in low-light visual disturbance.\n        </li>\n<li>\n          Post-hoc analysis from MIRA-2 Phase 3 study will be shown, indicating RYZUMVI can improve image quality when reversing pharmacologically induced pupil dilation.\n        </li>\n<li>\n          Phase 1 study results for varenicline solution nasal spray in healthy Japanese adults will be presented, focusing on tear-related effects.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VTRS\">Viatris Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604100659PR_NEWS_USPR_____NE31355) on April 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-10 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Viatris outlined four data presentations for ASCRS Annual Meeting in Washington, D.C., April 10-13, including new Phase 3 readouts for phentolamine ophthalmic solution programs.\n        </li>\n<li>\n          Full results from VEGA-3, Phase 3 study of MR-141 for presbyopia, will be presented, highlighting durable improvement in near vision.\n        </li>\n<li>\n          LYNX-2 Phase 3 data on MR-142 in post-refractive surgery patients will be presented as an encore, supporting use in low-light visual disturbance.\n        </li>\n<li>\n          Post-hoc analysis from MIRA-2 Phase 3 study will be shown, indicating RYZUMVI can improve image quality when reversing pharmacologically induced pupil dilation.\n        </li>\n<li>\n          Phase 1 study results for varenicline solution nasal spray in healthy Japanese adults will be presented, focusing on tear-related effects.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VTRS\">Viatris Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604100659PR_NEWS_USPR_____NE31355) on April 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2087621335.USD","symbol_name":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL2swvqM:1","article_id":"2626191297","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626191297","pubTimestamp":1775818786,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viatris outlined four data presentations for ASCRS Annual Meeting in Washington, D.C., April 10-13, including new Phase 3 readouts for phentolamine ophthalmic solution programs.Full results from VEGA-3, Phase 3 study of MR-141 for presbyopia, will be presented, highlighting durable improvement in near vision.LYNX-2 Phase 3 data on MR-142 in post-refractive surgery patients will be presented as an encore, supporting use in low-light visual disturbance.Post-hoc analysis from MIRA-2 Phase 3 study will be shown, indicating RYZUMVI can improve image quality when reversing pharmacologically induced pupil dilation.Phase 1 study results for varenicline solution nasal spray in healthy Japanese adults will be presented, focusing on tear-related effects.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4007":"制药","BK4583":"猴痘概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","VTRS":"Viatris Inc."},"translate_title":"Viatris将在ASCRS会议上展示MR-141老花眼3期试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9},"content_text":"Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting\n    \n\n\n          Viatris outlined four data presentations for ASCRS Annual Meeting in Washington, D.C., April 10-13, including new Phase 3 readouts for phentolamine ophthalmic solution programs.\n        \n\n          Full results from VEGA-3, Phase 3 study of MR-141 for presbyopia, will be presented, highlighting durable improvement in near vision.\n        \n\n          LYNX-2 Phase 3 data on MR-142 in post-refractive surgery patients will be presented as an encore, supporting use in low-light visual disturbance.\n        \n\n          Post-hoc analysis from MIRA-2 Phase 3 study will be shown, indicating RYZUMVI can improve image quality when reversing pharmacologically induced pupil dilation.\n        \n\n          Phase 1 study results for varenicline solution nasal spray in healthy Japanese adults will be presented, focusing on tear-related effects.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604100659PR_NEWS_USPR_____NE31355) on April 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626191297","isCrawlerRequest":true}